StockData

Harvard Bioscience vs Precipio

HBIO and PRPO side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HBIO and PRPO compare

Harvard Bioscience and Precipio are about the same size, with market caps of $40.6M and $35.7M.

Precipio grew revenue faster over the last twelve months (28.0% versus −1.1% for Harvard Bioscience).

Precipio scores higher on the StockData Score (5 against 3 for Harvard Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHBIOPRPO
Size and price
Market cap$40.6M$35.7M
Share price$8.91$19.96
Change, 1 year53.0%2.3%
Change, 5 years−87.1%−47.7%
Beta (5Y)2.010.31
Employees33961
StockData Score
Total score35 (better)
Valuation score01 (better)
Growth score12 (better)
Performance score1 (better)0
Health score12 (better)
Dividend score00
Valuation
P/S0.5× (better)1.3×
P/B5.5×–
P/FCF–45.3×
FCF yield−2.8%2.2% (better)
Fair value$6.45–
Margin of safety−38.1%–
Growth
Revenue growth (TTM)−1.1%28.0% (better)
Revenue growth, 5Y average−3.3%31.6% (better)
Profitability
Gross margin58.2% (better)44.1%
Operating margin−0.28% (better)−5.7%
Net margin−11.9%–
FCF margin−1.3%2.9% (better)
Return on equity−89.9%–
Return on invested capital−0.84%–
Financial health
Debt / equity4.95–
Current ratio1.87 (better)1.77
Altman Z-score−2.22 (better)−2.40
Piotroski F-score37 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions36.9%8.8%
Held by insiders–20.4%
Insider net buying, 12 months$202K (better)−$98.8K
Short interest, % of float–3.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.